Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide
Synergistic NPY2R and GCGR/GLP-1R agonism provides an attractive mode of action for clinically relevant weight loss in patients with obesity.
Authors
- Tamara Baader-Pagler
- Albert Brennauer
- Wolfgang Reindl (ORCID: https://orcid.org/0000-0002-6982-8506)
- Achim Grube
- Peter Haebel
- Angela Baljuls
- Eric Martel (ORCID: https://orcid.org/0000-0001-8015-7283)
- Jacob Hecksher‐Sørensen (ORCID: https://orcid.org/0000-0002-5516-6177)
- Anouk Oldenburger (ORCID: https://orcid.org/0000-0002-0264-2467)
- Lise Biehl Rudkjaer
- Robert Augustin
- Jens Markus Borghardt (ORCID: https://orcid.org/0000-0001-7000-9308)
- Stefan Peters (ORCID: https://orcid.org/0000-0003-0780-9016)
- Bartlomiej Krawczyk
- Tina Zimmermann
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Gubra (Denmark) (DK)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1016/j.molmet.2025.102205
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Boehringer Ingelheim